ImmuCell Corporation (Nasdaq: ICCC) announced unaudited financial results for the quarter ended September 30, 2026, reporting a significant increase in sales and profitability compared to the prior year period.
For the third quarter of 2026, the company reported product sales of approximately $8.0 million. This represents a 46.0% increase compared to the $5.5 million in sales recorded for the same period in 2025. The company noted that this growth was supported by distributor out-the-door volume growth of 18% over 2025 and was aided by the absence of distributor restocking headwinds that had impacted the prior year.
On the income statement, ImmuCell achieved a net income of $953,000 for the quarter, or $0.10 per diluted share. This is a substantial improvement compared to the net loss of $140,000, or ($0.02) per basic share, reported for the third quarter of 2025. The company also reported a gross margin of 44.2% for the quarter, an increase of 130 basis points compared to the 42.9% margin in the prior year.
The company’s balance sheet showed strong growth in liquidity. As of September 30, 2026, cash and cash equivalents totaled $7.9 million, a significant increase from $3.8 million as of December 31, 2025. This increase was attributed in part to a $2 million settlement payment received in May 2026. Net working capital also increased to approximately $16.9 million from $13.0 million.
In other corporate developments, ImmuCell stated that it has terminated its At-The-Market offering due to its strong cash position. Additionally, the company announced that it has negotiated a new, larger $3 million line of credit with its bank, which is expected to be signed during the fourth quarter of 2026.
Management highlighted that the expanded commercial team is delivering solid revenue growth and that the company is investing in capacity expansion and colostrum sourcing capabilities for future demand, with those efforts projected to be completed on time and within budget.
